SRPK1/ABCG2 Inhibitor SCO-101

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C175512

C175512

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

GDC

An orally bioavailable inhibitor of the serine/arginine-rich splicing factor protein kinase 1 (SRPK1) and the ATP-binding cassette sub-family G member 2 (ABCG2), with potential chemosensitizing and antineoplastic activities. Upon oral administration, SRPK1/ABCG2 inhibitor SCO-101 targets, binds to and inhibits the activity of SRPK1 and ABCG2. Inhibition of the cellular efflux pump ABCG2 by SCO-101 prevents the efflux of co-administered chemotherapeutic agents from cancer cells. This may abrogate cancer cell drug resistance and may re-sensitize cancer cells to the chemotherapeutic agents. Inhibition of SRPK1 kinase by SCO-101 inhibits the SRPK1-mediated phosphorylation of splicing factors rich in serine/arginine domains, thereby inhibiting the activation of proteins that are involved in the regulation of alternative splicing. This may inhibit cancer cell proliferation. SRPK1 is upregulated in various cancer cell types. Its upregulation is correlated with higher tumor staging, grading, and shorter survival.

SCO 101

SCO101

SRPK1/ABCG2 Inhibitor SCO-101

SCO-101

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

SRPK1/ABCG2 Inhibitor SCO-101

SRPK1/ABCG2 Inhibitor SCO-101

803025

CL1412867

803025

803025

SRPK1/ABCG2 Inhibitor SCO-101

Thesaurus:C175512

SRPK1/ABCG2 Inhibitor SCO-101

Pharmacologic Substance

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825